Monoclonal Antibodies Clinical Trial Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

Key Takeaways from the Monoclonal Antibodies Competitive Landscape Report Key Takeaways from the Monoclonal Antibodies Competitive Landscape Report Request a sample and discover the recent advances in monoclonal antibodies treatment @Monoclonal Antibodies Competitive Landscape Report Monoclonal Antibodies Overview Monoclonal antibody (mAb) allows for a far more accurate understanding of the humoral immune response by dissecting it into specific B-lymphocyte populations...

Key Takeaways from the Monoclonal Antibodies Competitive Landscape Report

Request a sample and discover the recent advances in monoclonal antibodies treatment @ Monoclonal Antibodies Competitive Landscape Report

Monoclonal Antibodies Overview

Monoclonal antibody (mAb) allows for a far more accurate understanding of the humoral immune response by dissecting it into specific B-lymphocyte populations. A wide variety of mAbs have been developed to target antigens found in the kidney, bladder, and prostate. The importance of therapeutic monoclonal antibodies is growing year by year. Their very specific antigen targeting can give very effective medical treatment, and the advent of molecular-targeted medicine is enabling the development of a new generation of therapeutic medicines. However, there is one major hurdle to overcome. Although all proteins have original native intact structures for their own distinct functions, the majority of developed therapeutic monoclonal antibodies exhibit selectivity for the primary structures of target antigens. Stereo-specific monoclonal antibodies that recognize target antigen conformational features may thus provide a far more diverse approach. Their use may alter the fundamental assumptions underlying the use of therapeutic antibodies.

Find out more about monoclonal antibodies drugs @ Monoclonal Antibodies Treatment

Monoclonal Antibodies Pipeline Analysis: Drug Profile

Ianalumab: Novartis

Ianalumab (VAY736) is a novel, defucosylated human IgG1 monoclonal antibody that targets the TNF family's human B cell-activating factor (BAFF). The BAFF receptor is mostly expressed in B cells and plays an important role in B cell maturation, activation, and survival. VAY736 binds to the BAFF receptor and inhibits BAFF binding to the BAFF-R, preventing BAFF-R-mediated signaling in B cells. It is also designed to eradicate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). By removing fucose residues from the carbohydrate moiety connected to the Fc component of the antibody, ianalumab's ADCC activity is considerably increased. It is now being studied in Phase III clinical trials for the treatment of Sjögren's syndrome, Lupus nephritis, Immune thrombocytopenia, Systemic Lupus Erythematosus, and warm autoimmune hemolytic anemia. In addition, the molecule is being evaluated in Phase II development for Idiopathic pulmonary fibrosis, Multiple Sclerosis, and other diseases.

Ziltivekimab: Novo Nordisk

Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb) that targets residual inflammatory cardiovascular risk in patients with severe chronic kidney disease (CKD). Ziltivekimab is being developed as a medication to minimize the incidence of significant cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients with moderate to severe CKD, ASCVD, and inflammation are at high risk of an adverse cardiovascular event, and there are no licensed medications to reduce this risk. Interleukin-6 (IL-6) has been established to be an independent, causative component of ASCVD in human genetic research and preclinical studies. The drug is currently in Phase III testing for the treatment of patients with moderate to severe chronic renal disease.

A snapshot of the Monoclonal Antibodies Pipeline Drugs mentioned in the report:

 

Learn more about the emerging monoclonal antibodies pipeline drugs @ Monoclonal Antibodies Clinical Trials

Scope of the Monoclonal Antibodies Competitive Landscape Report 

Dive deep into rich insights for new drugs for monoclonal antibodies treatment, visit @ Monoclonal Antibodies Drugs

Table of Contents

 

For further information on the monoclonal antibodies pipeline therapeutics, reach out @ Monoclonal Antibodies Treatment Drugs

Related Reports

Sjogren's Syndrome Pipeline

Sjogren's Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Sjogren's syndrome companies, including Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, among others.

Bladder Cancer Market

Bladder Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bladder cancer companies including RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, among others.

Multiple Sclerosis Pipeline

Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., among others.

Colorectal Cancer Market

Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key colorectal cancer companies including Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, among others.

For more insights, visit our blog section @ Healthcare Blogs

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Contact Us
Shruti Thakur 
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

 

View original content:https://www.prnewswire.co.uk/news-releases/monoclonal-antibodies-clinical-trial-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301842033.html